Physician profile
Heidi A Fields
NPI 1124473046
$1,285.07
in general payments reported to CMS, 2019-2025
23 companies · $572 in 2025
The $572 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2023: $283 · 2024: $293 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.22 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $130.49 | 2021-2025 | |
| Exact Sciences Corporation | $104.83 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $99.49 | 2025 | Keveyis, Gvoke Hypopen |
| Amgen INC. | $82.46 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $78.65 | 2021-2025 | Bexsero, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $71.20 | 2021 | |
| Pfizer INC. | $65.23 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.24 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $49.04 | 2024-2025 | Spravato |
| Novo Nordisk INC | $47.41 | 2023-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $39.66 | 2024-2025 | Vaxelis, Vaxneuvance, Rotateq |
| Ironshore Pharmaceuticals INC. | $37.74 | 2024 | |
| Collegium Pharmaceutical, INC. | $34.37 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.13 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.88 | 2025 | Breztri |
| Seqirus USA INC | $20.52 | 2025 | Flucelvax |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2025 | Austedo Xr |
| Phadia US INC. | $17.24 | 2024 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $16.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.70 | 2025 | |
| Abbott Laboratories | $13.52 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $13.29 | 2023 | Myrbetriq, Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.